-+ 0.00%
-+ 0.00%
-+ 0.00%

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Barchart·01/08/2026 08:05:00
Listen to the news

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company’s founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience and who has served on the Tango Board of Directors since 2018, who will drive the next phase of company growth.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.